SGLT-2抑制剂治疗慢性肾脏病的药物经济学系统评价

Pharmacoeconomic Evaluation of SGLT2 inhibitor in the Treatment of Chronic Kidney Disease：a Systematic Review

关键词:  钠-葡萄糖协同转运蛋白抑制剂  慢性肾病  系统评价  药物经济学

Key words:  SGLT2 inhibitor  chronic kidney disease  Systematic review  Pharmacoeconomics

摘要:

摘要：目的 综述SGLT-2抑制剂用于治疗慢性肾脏病的药物经济性评价方法和结果。方法 检索 PubMed、Medline、Cochrane图书馆、中国知网(CNKI)、维普网 (VIP)、万方数据发表的SGLT-2抑制剂用于慢性肾脏病治疗的经济学评价文献并对其进行综述，检索时限均为建库至2024年7月。结果 共纳入14篇SGLT-2抑制剂用于治疗慢性肾脏病的药物经济学研究，所有文献都显示标准治疗基础上联合SGLT-2抑制剂比不联合更具经济性。结论 纳入的文献多数用马尔科夫模型，纳入的SGLT-2抑制剂包括达格列净、卡格列净和恩格列净，在意愿支付阈值下都比标准治疗具成本-效果优势。

Abstract:

ABSTRACT: OBJECTIVE To review the pharmacoeconomic evaluation methods and findings of SGLT-2 inhibitors for the treatment of chronic kidney disease. METHODS Search economic evaluation studies of SGLT-2 inhibitors for chronic kidney disease on databases such as PubMed, Medline, Cochrane Library, CNKI, VIP Database and Wanfang Database were retrieved from inception to July, 2024. RESULTS A total of 14 pharmacoeconomic studies on the use of SGLT-2 inhibitors for treating chronic kidney disease were included, all of which demonstrated that combination therapy with SGLT-2 inhibitors on top of standard treatment was more cost-effective than standard treatment alone. CONCLUSION Most included studies employed Markov models, with dapagliflozin and canagliflozin and empagliflozin showing cost-effectiveness over standard treatment at various willingness-to-pay thresholds.